Hyperactivation of mTORC1 drives acquired resistance to the pan -HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers Meeting Abstract

  

Authors:	Sudhan, D. R.; Guerrero-Zotano, A.; Won, H.; Ericsson, P. G.; Liu, Q.; Dugger, T.; Koch, J.; Schram, A.; Servetto, A.; Cutler, R.; Lalani, A.; Bryce, R.; Auerbach, A.; Hanker, A.; Arteaga, C. L.
Abstract Title:	Hyperactivation of mTORC1 drives acquired resistance to the pan -HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
Meeting Title:	110th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title:	Cancer Research
Volume:	79
Issue:	13 Suppl.
Meeting Dates:	2019 Mar 29-Apr 3
Meeting Location:	Atlanta, GA
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2019-07-01
Language:	English
ACCESSION:	WOS:000488129901503
DOI:	10.1158/1538-7445.Sabcs18-329
PROVIDER:	wos
Notes:	Meeting Abstract: 329 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/156092